JUNO THERAPEUTICS, INC.
SEATTLE, WA

Juno Therapeutics, Inc., established on May 25, 2017, headquartered in Seattle, is a forward-thinking biotechnology company that has been absorbed into Celgene. The firm's mission centers around transforming the landscape of medical treatment for cancer and other grave diseases through strategic investment in scientific research, advanced manufacturing capabilities, and dedicated human resources. Formerly operating under its proprietary brand, Juno Therapeutics now operates as a subsidiary within Celgene, extending its global footprint with locations including Juno Therapeutics GmbH in G"ottingen and Munich, Germany. These subsidiaries are positioned at Rudolf-Wissell-Straße 28, 37079 for the Gottingen site. Juno Therapeutics was incorporated under the Florida business model Dos FLSA with a filing number F17000002386, categorized as a Foreign Corporation Operating Purpose (FORP). The company's initial registration lists its mailing address as 400 Dexter Avenue North, Suite 1200, Seattle, WA, 98109, US. Communication is facilitated through their corporate phone line at (206) 582-1600, and more information can be accessed via their official website, junotherapeutics.com. As of April 23, 2024, the company filed its annual report for the year 2024. The fiscal operations are cataloged under the Federal Employer Identification Number (FEI) 46-3656275. The leadership team comprises a distinguished group of officers and directors such as Elisabeth S. Bradley serving as Assistant, Kimberly M. Jablonski holding the position of Secretary, and Lisa A. Atkins also contributing as an Assistant.